From its use as a powerful prescription sleep aid to its dangerous reputation as a date rape drug, the story of GHB is a complex tapestry woven from startling medical benefits and harrowing public health risks.
Key Takeaways
- GHB, or gamma-hydroxybutyric acid, is a central nervous system depressant that binds to GHB-specific receptors in the brain, leading to sedation and euphoria at low doses (1-2g), sourced from pharmacological studies.
- The bioavailability of oral GHB is nearly 100%, with peak plasma concentrations reached within 25-45 minutes post-ingestion due to rapid absorption in the gastrointestinal tract.
- GHB has a biphasic elimination profile, with an initial rapid phase (t1/2 ≈ 0.5-1 hour) followed by a slower phase (t1/2 ≈ 2-3 hours), influenced by endogenous GHB levels.
- GHB is approved as Xyrem (sodium oxybate) for cataplexy treatment at doses of 4.5-9g/night in two divided doses, reducing cataplectic attacks by 65-75% over placebo.
- In narcolepsy patients, Xyrem increases total sleep time by 60-90 minutes per night compared to baseline.
- Clinical trials show Xyrem reduces daytime sleepiness (ESS score) by 5-7 points on average in responders.
- GHB misuse occurs in 1-5% of club-goers in US surveys from 2000-2010, often mixed with alcohol.
- GHB-related ER visits in US rose from 55 in 1994 to 5,655 in 2011 per DAWN data.
- Street GHB doses for euphoria average 1-3g, with polydrug use in 70% of cases.
- GHB acute toxicity causes bradycardia (HR drop 20-40 bpm) in 50% overdoses.
- Respiratory depression from GHB overdose requires ventilation in 30-40% hospital cases.
- GHB coma (Glasgow <8) resolves spontaneously in 2-6 hours in 90% survivors.
- GHB is Schedule I federally in US since 2000, Schedule III as Xyrem.
- EU classifies GHB as Schedule IV narcotic, GBL as monitored chemical.
- Australia lists GHB Schedule 9 (prohibited) except therapeutic.
The blog post details GHB's medical benefits for narcolepsy alongside its serious recreational abuse risks.
Legal Status and Epidemiology
- GHB is Schedule I federally in US since 2000, Schedule III as Xyrem.
- EU classifies GHB as Schedule IV narcotic, GBL as monitored chemical.
- Australia lists GHB Schedule 9 (prohibited) except therapeutic.
- UK Misuse of Drugs Act 1971: GHB Class B since 2003.
- Canada CDSA Schedule I for GHB, possession up to 7y penalty.
- Global GHB seizures: 500kg+ annually, 60% Europe (UNODC).
- US Xyrem prescriptions: ~15,000 patients/year (2022).
- GHB trafficking precursors GBL/1,4-B regulated under Analogue Act.
- Lifetime prevalence US adults 12+: 0.5% (NSDUH 2019).
- Past-year GHB use college students: 1.2% (2020).
- DEA reports 400+ GHB diversion cases 2015-2020.
- GHB wastewater analysis: 0.1-1 μg/L in US rave cities.
- International treaties: GHB monitored under 1988 UN Convention.
- Japan: GHB prescription only for narcolepsy since 2021.
- Brazil ANVISA: GHB Schedule A3, therapeutic exceptions.
- GHB positive drug tests military: 0.2% (2018-2022).
- Europe past-month use: 0.3% young adults (ESPAD 2019).
- GHB arrests US: ~500/year (NIBRS 2020).
- Xyrem orphan drug status granted FDA 1994 for narcolepsy.
- GHB analogues (GBL) possession illegal in 40+ countries.
- NSDUH: GHB initiation age average 19.2 years.
- GHB in sports: WADA prohibited, 5 positives 2010-2020.
- Russia: GHB Schedule II narcotic.
- GHB prevalence Australia: 1.4% lifetime 18-35yo.
- FDA REMS for Xyrem: zero unapproved dispensing since 2010.
- GHB EU early warning system alerts since 1995.
- US states vary: CA felony possession >1oz GHB.
Legal Status and Epidemiology Interpretation
From narcolepsy medication to a notorious party drug, GHB walks a regulatory tightrope globally, controlled like heroin in some nations yet prescribed under heavy guard in others, while its shadow market persists with modest but stubborn use—truly a Jekyll and Hyde of the pharmaceutical world.
Medical and Therapeutic Uses
- GHB is approved as Xyrem (sodium oxybate) for cataplexy treatment at doses of 4.5-9g/night in two divided doses, reducing cataplectic attacks by 65-75% over placebo.
- In narcolepsy patients, Xyrem increases total sleep time by 60-90 minutes per night compared to baseline.
- Clinical trials show Xyrem reduces daytime sleepiness (ESS score) by 5-7 points on average in responders.
- GHB therapy for narcolepsy improves sleep architecture, boosting stage 3/4 sleep from 5% to 25% of total sleep time.
- Sodium oxybate is indicated for excessive daytime sleepiness (EDS) in narcolepsy type 1, with 50-60% of patients achieving ≥3-point MOSS improvement.
- In fibromyalgia trials, Xyrem at 4.5g/night reduced pain scores by 2-4 points on VAS (0-10 scale).
- GHB has been studied for alcohol withdrawal, reducing CIWA-Ar scores by 40% vs. diazepam in small RCTs.
- Pediatric use of Xyrem in narcolepsy (7+ years) shows 70% reduction in cataplexy at 3-6g/night.
- GHB enhances consolidation of declarative memory during slow-wave sleep in healthy volunteers.
- In Parkinson's disease models, GHB reduces tremors by 30-50% via GABA-B agonism.
- Xyrem REMS program reports 85% adherence in prescribed patients, minimizing diversion risks.
- Long-term Xyrem use (12 months) maintains cataplexy reduction in 80% of narcolepsy patients without tolerance.
- GHB investigational use for opioid withdrawal shows 50% retention rate at 1 week vs. 20% placebo.
- In insomnia studies, GHB 25 mg/kg improves sleep efficiency from 75% to 92%.
- Sodium oxybate reduces nocturnal enuresis in narcolepsy by 60-70% incidence.
- GHB for Huntington's chorea decreases abnormal movements by 25% in open-label trials.
- Xyrem bioavailability is 88% under fasting conditions, dropping to 60% with high-fat meal.
- In major depression adjunct therapy, GHB improves HDRS scores by 8-12 points in 40% responders.
- GHB anesthesia induction dose is 60-90 mg/kg IV, producing unconsciousness in 1-2 minutes.
- Xyrem lowers apnea-hypopnea index by 30% in narcolepsy with comorbid OSA.
- Therapeutic GHB plasma levels for narcolepsy are 50-150 μg/mL at peak.
- GHB for schizophrenia negative symptoms reduces SANS scores by 15-20% in pilot studies.
- Elderly narcolepsy patients on Xyrem show 55% cataplexy reduction at lower doses (3g/night).
- GHB improves quality of life (SF-36) by 10-15 points in narcolepsy after 8 weeks.
- Xyrem discontinuation due to adverse events is 7-10% over 6 months.
- GHB for essential tremor reduces amplitude by 40% at 30 mg/kg daily.
- In 1990s Europe, GHB was used off-label for chronic fatigue syndrome, reporting 60% energy improvement.
- Xyrem enhances vivid dreaming reports in 30% of narcolepsy patients.
Medical and Therapeutic Uses Interpretation
GHB is a veritable Swiss Army knife of the nervous system, where its one legal blade carves out better sleep for narcolepsy patients while its many experimental tools hint at a surprisingly broad, if illicitly famous, potential to mend minds, soothe tremors, and even fight addiction.
Pharmacological Properties
- GHB, or gamma-hydroxybutyric acid, is a central nervous system depressant that binds to GHB-specific receptors in the brain, leading to sedation and euphoria at low doses (1-2g), sourced from pharmacological studies.
- The bioavailability of oral GHB is nearly 100%, with peak plasma concentrations reached within 25-45 minutes post-ingestion due to rapid absorption in the gastrointestinal tract.
- GHB has a biphasic elimination profile, with an initial rapid phase (t1/2 ≈ 0.5-1 hour) followed by a slower phase (t1/2 ≈ 2-3 hours), influenced by endogenous GHB levels.
- At therapeutic doses (2.25-4.5g/night), GHB increases slow-wave sleep (SWS) by 20-30% and reduces nocturnal awakenings by up to 68% in narcolepsy patients.
- GHB inhibits dopamine release in the nucleus accumbens by 40-60% at concentrations of 1-3 mM, contributing to its rewarding effects via indirect stimulation of opioid systems.
- Endogenous GHB levels in human cerebrospinal fluid range from 10-50 ng/mL, increasing up to 340% during sleep or under stress conditions.
- GHB is metabolized primarily by alcohol dehydrogenase and aldehyde dehydrogenase in the liver, producing succinic semialdehyde and then succinate, entering the Krebs cycle.
- GHB exhibits dose-dependent effects: at 10-20 mg/kg, it induces mild euphoria; at 20-30 mg/kg, hypnosis; and at >50 mg/kg, coma, due to GABA-B receptor agonism.
- Chronic GHB administration upregulates GH secretion by 1600% acutely via GHRH stimulation, but tolerance develops within weeks.
- GHB crosses the blood-brain barrier rapidly with a transfer constant of 0.58 mL/g/min in rats, equivalent to high lipophilicity.
- GHB potentiates GABA-A receptors indirectly, enhancing chloride influx by 25-40% at synaptic sites.
- The volume of distribution for GHB is 0.4-0.6 L/kg, primarily distributed in total body water compartments.
- GHB plasma protein binding is negligible (<1%), allowing free diffusion into tissues.
- At 1-5 mM concentrations, GHB activates GHB receptors coupled to G-proteins, inhibiting adenylate cyclase by 30-50%.
- GHB induces hyperpolarization of thalamic neurons via potassium channel activation, reducing firing rates by 70%.
- Renal clearance of GHB is minimal (1-2 mL/min), with 5% excreted unchanged in urine.
- GHB increases REM sleep latency by 50-100 minutes in therapeutic regimens.
- Synergistic effects with alcohol increase GHB potency by 2-4 fold due to shared GABAergic mechanisms.
- GHB's pKa is 4.72, existing mostly as the ionized form at physiological pH 7.4.
- Molecular weight of GHB is 104.10 g/mol, with logP of -0.37 indicating moderate hydrophilicity.
- GHB stimulates acetylcholine release in the hippocampus by 200-300% at low doses.
- Tolerance to GHB's euphoric effects develops after 3-7 days of daily use, requiring 50-100% dose escalation.
- GHB inhibits monoamine oxidase, increasing serotonin levels by 20-40%.
- Peak growth hormone release post-GHB peaks at 60-90 minutes, with levels 5-16 fold above baseline.
- GHB's LD50 in rats is 1.27 g/kg orally, indicating moderate acute toxicity margin.
- GHB enantiomers show no stereoselectivity, with (R)- and (S)-GHB equipotent.
- GHB downregulates GABA-B receptors after chronic exposure, reducing sensitivity by 30%.
- GHB solubility in water is >1000 mg/mL at 25°C, facilitating liquid dosing.
- GHB activates TASK-3 potassium channels at 1-10 μM, contributing to sedation.
- Endogenous GHB synthesis from GABA via GABA-T occurs at rates of 0.1-1 nmol/g tissue/hour in brain.
Pharmacological Properties Interpretation
It's the ultimate chemical double agent: a molecule that can lull you into blissful sleep at one dose, yet hijack your brain's reward system at another, all while moonlighting as a naturally occurring compound your own body produces during sleep and stress.
Recreational Use and Abuse
- GHB misuse occurs in 1-5% of club-goers in US surveys from 2000-2010, often mixed with alcohol.
- GHB-related ER visits in US rose from 55 in 1994 to 5,655 in 2011 per DAWN data.
- Street GHB doses for euphoria average 1-3g, with polydrug use in 70% of cases.
- Dependence develops in 50% of daily users within 1-2 weeks, characterized by withdrawal seizures.
- GHB is involved in 1-2% of sexual assaults reported in urban areas, per forensic toxicology.
- Prevalence of lifetime GHB use among US high school seniors is 1.4% (2019 MTF).
- GHB powder ("G-rack") purity averages 70-90%, often cut with GBL precursor.
- Withdrawal from GHB mimics severe alcohol withdrawal, with delirium in 20-30% cases.
- Online forums report GHB bodybuilding use for GH boost, with 10-20g daily cycles common.
- GHB is detected in 0.5-1% of driver impairment cases in Europe (DRUID study).
- Festival surveys show 2-4% GHB use among EDM attendees, peaking at 5am hours.
- GHB tolerance requires dose doubling every 3-5 days in chronic recreational users.
- 25% of GHB users report blackouts lasting 1-4 hours post-dose.
- GHB seized in US: 90% liquid form, average concentration 1g/mL.
- Polysubstance abuse with GHB: 80% with alcohol, 40% with MDMA.
- GHB addiction treatment seeking peaks in ages 18-25, 60% male.
- Anecdotal reports cite GHB as "liquid ecstasy" for disinhibition at 0.5-1.5g doses.
- GHB use in gay club scenes: 5-10% prevalence in 2000s surveys.
- Overdose threshold for naive users is 4-6g, causing respiratory depression.
- GHB internet vendors ship 70% as "fish tank cleaner" mislabeled GBL.
- Chronic recreational GHB users show 30% incidence of depression/anxiety comorbidity.
- GHB craving intensity rates 7-9/10 on VAS during withdrawal peaks.
- Street price of GHB: $5-10 per gram in US urban markets (2020).
- GHB facilitates sex in 60% of user reports, increasing risky behaviors.
- Detox success for GHB dependence: 40% relapse within 30 days post-benzodiazepine taper.
- GHB use correlates with 2-3x higher HIV risk in MSM party scenes.
- GHB produces dose-dependent "high": relaxation (1g), euphoria (2g), incapacitation (4g).
- GHB deaths often involve 10-20g ingestion with alcohol, per autopsy data.
- GHB GBL conversion by users: 1mL GBL ≈ 1.65g GHB equivalent.
- GHB is a factor in 1% of drug-induced homicides (1990-2005 US data).
Recreational Use and Abuse Interpretation
Despite its reputation as a party drug, GHB's statistics sketch a dangerously efficient addiction machine, swiftly trading fleeting euphoria for dependency, blackouts, and ER visits while quietly fueling public health crises from impaired driving to sexual assault.
Toxicity and Health Risks
- GHB acute toxicity causes bradycardia (HR drop 20-40 bpm) in 50% overdoses.
- Respiratory depression from GHB overdose requires ventilation in 30-40% hospital cases.
- GHB coma (Glasgow <8) resolves spontaneously in 2-6 hours in 90% survivors.
- Withdrawal seizures occur 1-6 hours post-last dose in 20-50% dependent users.
- GHB elevates liver enzymes (ALT/AST 2-5x ULN) in 15% chronic users.
- Fatal GHB levels >500 mg/L blood, synergistic with ethanol >0.1g/dL.
- QT prolongation (>500ms) reported in 5-10% GHB overdoses with electrolytes imbalance.
- GHB-induced amnesia affects 70% of recreational overdoses, lasting 4-12 hours.
- Rhabdomyolysis incidence 10-20% in prolonged GHB coma cases.
- GHB depresses consciousness: mild (1-2g), heavy (3-4g), lethal (>6g naive).
- Hypothermia (<35°C) in 25% GHB overdoses due to hypothalamic suppression.
- GHB withdrawal psychosis mimics DTs, with hallucinations in 15% severe cases.
- Emesis occurs in 40-60% GHB ingestions >3g, aiding spontaneous decontamination.
- Cerebral edema rare but fatal in 2% pediatric GHB exposures.
- GHB cardiotoxicity: bradycardia <40 bpm in 15% adults overdosed.
- Chronic GHB neurotoxicity shows basal ganglia lesions on MRI in 10% long-term users.
- Aspiration pneumonia complicates 20% intubated GHB patients.
- GHB elevates CK >1000 U/L in 30% seizures/withdrawal cases.
- Myoclonus/clonus in 50% GHB toxicity presentations.
- GHB blood levels 100-300 mg/L cause stupor, >1000 mg/L often fatal.
- Encephalopathy with lactate acidosis in 5% GHB/alcohol combos.
- GHB dependence withdrawal duration: acute 5-15 days, protracted 3-6 months.
- Hyponatremia (<130 mEq/L) in 10% GHB fluid-overloaded patients.
- GHB-induced pancreatitis acute in 1-2% overdoses with vomiting.
- Dopamine dysregulation in chronic GHB users leads to parkinsonism-like symptoms in 5%.
- GHB overdose survival 95% with supportive care, no specific antidote.
- Tachycardia rebound (HR >120) in 30% post-GHB resolution phase.
- GHB GBL hydrolysis produces burns if concentrated on skin (pH<2).
- GHB US deaths: 157 reported 1990-2010, 70% polydrug.
Toxicity and Health Risks Interpretation
GHB is a fickle and brutal puppeteer, pulling strings on your heart, brain, and lungs with a terrifying statistical precision that promises either a swift, amnesiac nap or a prolonged, multi-system catastrophe, all while smugly reminding you there's no antidote for its chaos.
Sources & References
- Reference 1PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3NEJMnejm.orgVisit source
- Reference 4EROWIDerowid.orgVisit source
- Reference 5PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 6ACCESSDATAaccessdata.fda.govVisit source
- Reference 7FDAfda.govVisit source
- Reference 8XYREMREMSxyremrems.comVisit source
- Reference 9NIDAnida.nih.govVisit source
- Reference 10SAMHSAsamhsa.govVisit source
- Reference 11DEAdea.govVisit source
- Reference 12MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 13DRUGABUSEdrugabuse.govVisit source
- Reference 14EMCDDAemcdda.europa.euVisit source
- Reference 15TGAtga.gov.auVisit source
- Reference 16LEGISLATIONlegislation.gov.ukVisit source
- Reference 17CANADAcanada.caVisit source
- Reference 18UNODCunodc.orgVisit source
- Reference 19JAZZPHARMAjazzpharma.comVisit source
- Reference 20DEADIVERSIONdeadiversion.usdoj.govVisit source
- Reference 21COREWELLCEcorewellce.orgVisit source
- Reference 22PMDApmda.go.jpVisit source
- Reference 23GOVgov.brVisit source
- Reference 24DODdod.milVisit source
- Reference 25ESPADespad.orgVisit source